Clinical Trial Update: Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab with weekly paclitaxel followed by bevacizumab alone in relapsed ovarian sex-cord stromal tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Sex Cord-stromal Tumor

Drugs mentioned

• Bevacizumab (bevacizumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: ARCAGY/ GINECO GROUP | Conditions: Ovarian Sex-cord Stromal Tumor | Phase 2 | Status: COMPLETED